| Patient | Charles Darwin |
|---|---|
| Date of birth | 1809-02-12 |
| Identifiers | MRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967 |
| Document date | 2026-11-01 |
| Author | Bernard Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopy. Concerns: For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every week; Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomit; He worries about being taken ill in company and has begun to avoid gatherings and travel. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amitriptyline 25 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-04-14 to 1849-04-28 | completed | S |
| Amitriptyline 50 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-04-28 to 1849-05-12 | completed | S |
| Amitriptyline 75 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-05-12 | active | S |
| Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode | One spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a week | Nasal route | 1849-04-14 | active | S |
| Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode | Dissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episode | Oral route | 1849-04-14 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| CT enterography (CT of the small bowel with oral and intravenous contrast): normal small and large bowel, no obstruction, malrotation, stricture, or wall thickening; normal liver, gallbladder, pancreas, and kidneys | 1849-03-17 to 1849-03-17 | completed | S |
| Upper endoscopy (esophagogastroduodenoscopy) with duodenal biopsies: normal esophagus, stomach, and duodenum; no ulcer, obstruction, or retained food; duodenal biopsies normal | 1849-03-31 to 1849-03-31 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1848-10-14 | Influenza vaccine, 1848-1849 season | completed | S |
| 1842-06-11 | Tetanus, diphtheria, and acellular pertussis (Tdap) booster | completed | S |
| 1849-07-21 | Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| December 1831 | Palpitations and pain about the heart while waiting to sail on the Beagle; no doctor consulted | D (CLM-0003) |
| September 1837 | Palpitations, treated with rest in the country on his doctors' advice | D (CLM-0004) |
| June 1840 | Periodical vomiting, first mentioned in a letter; cause not recorded in the cited source | D (CLM-0005) |
| February 1849 | A winter of dreadful vomiting every week, with trembling hands and a swimming head, and incessant vomiting described in a letter; cause not recorded in the cited source | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every week | active | S |
| Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomit | active | S |
| He worries about being taken ill in company and has begun to avoid gatherings and travel | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.6 on 1849-03-03; Leukocytes [#/volume] in Blood by Automated count 6.4 on 1849-03-03; Platelets [#/volume] in Blood by Automated count 251 on 1849-03-03; Sodium [Moles/volume] in Serum or Plasma 140 on 1849-03-03; Potassium [Moles/volume] in Serum or Plasma 4.1 on 1849-03-03; Chloride [Moles/volume] in Serum or Plasma 103 on 1849-03-03; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 1849-03-03; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 1849-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1844)/1.73 sq M 104 on 1849-03-03; Glucose [Mass/volume] in Serum or Plasma 88 on 1849-03-03; Calcium [Mass/volume] in Serum or Plasma 9.5 on 1849-03-03; Albumin [Mass/volume] in Serum or Plasma 4.4 on 1849-03-03; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1849-03-03; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 1849-03-03; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 68 on 1849-03-03; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1849-03-03; Lipase [Enzymatic activity/volume] in Serum or Plasma 32 on 1849-03-03; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 1849-03-03; Cortisol [Mass/volume] in Serum or Plasma 14.2 on 1849-03-03; Tissue transglutaminase IgA Ab [Units/volume] in Serum 1.2 on 1849-03-03; IgA [Mass/volume] in Serum or Plasma 210 on 1849-03-03; Q-T interval corrected 436 on 1849-06-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1849-09-08; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1849-09-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1849-07-21; Total score [AUDIT-C] 2 on 1849-07-21; Cholesterol [Mass/volume] in Serum or Plasma 178 on 1849-07-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 1849-07-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 102 on 1849-07-21; Triglyceride [Mass/volume] in Serum or Plasma 90 on 1849-07-21 [S]
Strengths and supports: Supports: a settled household, absorbing scientific work, daily walks, and a habit of keeping careful notes that suits a symptom diary [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosis | active | provisional | R11.15 | S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory. |
| Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluation | resolved | confirmed | R11.2 | S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D). |
| Common cold, without a vomiting episode; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1849-03-03 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1849-03-03 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1849-03-03 | Platelets [#/volume] in Blood by Automated count | 251 | 10*3/uL | 135-317 10*3/uL | Normal | S |
| 1849-03-03 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1849-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1849-03-03 | Chloride [Moles/volume] in Serum or Plasma | 103 | mmol/L | 98-107 mmol/L | Normal | S |
| 1849-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 1849-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1849-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1844)/1.73 sq M | 104 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1849-03-03 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 1849-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1849-03-03 | Albumin [Mass/volume] in Serum or Plasma | 4.4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1849-03-03 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-55 U/L | Normal | S |
| 1849-03-03 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 8-48 U/L | Normal | S |
| 1849-03-03 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 68 | U/L | 40-129 U/L | Normal | S |
| 1849-03-03 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1849-03-03 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 13-60 U/L | Normal | S |
| 1849-03-03 | Thyrotropin [Units/volume] in Serum or Plasma | 1.6 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1849-03-03 | Cortisol [Mass/volume] in Serum or Plasma | 14.2 | ug/dL | 6.2-19.4 ug/dL | Normal | S |
| 1849-03-03 | Tissue transglutaminase IgA Ab [Units/volume] in Serum | 1.2 | U/mL | <=3.9 U/mL | Normal | S |
| 1849-03-03 | IgA [Mass/volume] in Serum or Plasma | 210 | mg/dL | 70-400 mg/dL | Normal | S |
| 1849-03-03 | Q-T interval corrected | 412 | ms | <=450 ms | Normal | S |
| 1849-06-09 | Q-T interval corrected | 436 | ms | <=450 ms | Normal | S |
| 1849-03-03 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 1849-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1849-06-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 1849-06-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1849-09-08 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 1849-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1849-07-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1849-07-21 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 1849-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 178 | mg/dL | <=200 mg/dL | Normal | S |
| 1849-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=40 mg/dL | Normal | S |
| 1849-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 102 | mg/dL | <=129 mg/dL | Normal | S |
| 1849-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 90 | mg/dL | <=149 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1849-03-03 | Body height | 183 | cm | S |
| 1849-03-03 | Body weight | 71.6 | kg | S |
| 1849-03-03 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1849-03-03 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1849-03-03 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1849-03-03 | Heart rate | 78 | /min | S |
| 1849-03-03 | Respiratory rate | 14 | /min | S |
| 1849-03-03 | Body temperature | 36.6 | Cel | S |
| 1849-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1849-04-14 | Body height | 183 | cm | S |
| 1849-04-14 | Body weight | 71.4 | kg | S |
| 1849-04-14 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 1849-04-14 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1849-04-14 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1849-04-14 | Heart rate | 76 | /min | S |
| 1849-04-14 | Respiratory rate | 14 | /min | S |
| 1849-04-14 | Body temperature | 36.7 | Cel | S |
| 1849-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1849-06-09 | Body height | 183 | cm | S |
| 1849-06-09 | Body weight | 72.4 | kg | S |
| 1849-06-09 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 1849-06-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1849-06-09 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1849-06-09 | Heart rate | 72 | /min | S |
| 1849-06-09 | Respiratory rate | 14 | /min | S |
| 1849-06-09 | Body temperature | 36.6 | Cel | S |
| 1849-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1849-09-08 | Body height | 183 | cm | S |
| 1849-09-08 | Body weight | 72.9 | kg | S |
| 1849-09-08 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1849-09-08 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1849-09-08 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1849-09-08 | Heart rate | 70 | /min | S |
| 1849-09-08 | Respiratory rate | 14 | /min | S |
| 1849-09-08 | Body temperature | 36.6 | Cel | S |
| 1849-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1849-05-19 | Body height | 183 | cm | S |
| 1849-05-19 | Body weight | 72.1 | kg | S |
| 1849-05-19 | Body mass index (BMI) [Ratio] | 21.5 | kg/m2 | S |
| 1849-05-19 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1849-05-19 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1849-05-19 | Heart rate | 84 | /min | S |
| 1849-05-19 | Respiratory rate | 16 | /min | S |
| 1849-05-19 | Body temperature | 37.8 | Cel | S |
| 1849-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1849-07-21 | Body height | 183 | cm | S |
| 1849-07-21 | Body weight | 72.6 | kg | S |
| 1849-07-21 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 1849-07-21 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1849-07-21 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1849-07-21 | Heart rate | 70 | /min | S |
| 1849-07-21 | Respiratory rate | 14 | /min | S |
| 1849-07-21 | Body temperature | 36.6 | Cel | S |
| 1849-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1849-03-03 | Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopy | finished | S |
| 1849-04-14 | Six-week follow-up: results, gastroenterology consultation, provisional diagnosis, prophylaxis, and abortive plan | finished | S |
| 1849-06-09 | Three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screen | finished | S |
| 1849-09-08 | Six-month review of response to prophylaxis | finished | S |
| 1849-05-19 | Same-day sick visit for a head cold | finished | S |
| 1849-07-21 | Preventive health visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Work-up between episodes: blood count, metabolic and liver panels, lipase, urinalysis, TSH, morning cortisol, celiac serology, a baseline ECG, CT enterography, and upper endoscopy | completed | GL-ANMS-CVS-2019 | S |
| Gastroenterology consultation to confirm the diagnosis and advise on prophylaxis, abortive treatment, and an emergency plan | completed | GL-ANMS-CVS-2019 | S |
| Symptom diary: date, prodrome, length and severity of each episode, triggers, medicines taken, and emergency visits | completed | GL-ANMS-CVS-2019 | S |
| Amitriptyline prophylaxis at bedtime: 25 mg, raised by 25 mg every two weeks to 75 mg (about 1 mg/kg), with an ECG at baseline, at about 50 mg, and at the target dose; judge the response after three months at target and continue for at least a year if it helps | completed | GL-ANMS-CVS-2019 | S |
| Abortive plan at the first sign of the prodrome: sumatriptan 20 mg nasal spray with ondansetron 8 mg dissolving tablet, a dark quiet room, and small sips of fluid; an individualized emergency department letter for episodes that do not settle | completed | GL-ANMS-CVS-2019 | S |
| Trigger management: regular meals and sleep, planning around travel and social events, early treatment of infections, and continued avoidance of cannabis | completed | GL-ANMS-CVS-2019 | S |
| Anxiety and mood: GAD-7 and PHQ-9 at the first visit and every three months; relaxation breathing, with cognitive behavioral therapy offered if symptoms persist | completed | GL-ANMS-CVS-2019, GL-USPSTF-ANX-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit | 1849-04-14 | completed | All tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultation | S |
| At least half as many episodes after three months at the target dose of prophylaxis | 1849-09-08 | completed | About two episodes a month before treatment; one brief episode, aborted at the prodrome, in the three months before the six-month review | S |
| Carry the abortive medicines and the emergency department letter, and use them at the prodrome | 1849-06-09 | completed | The one episode since starting treatment was treated at the prodrome and settled in about ten hours without an emergency visit; letter carried | S |
| QTc below 450 ms at the target amitriptyline dose | 1849-06-09 | completed | QTc 436 ms on 75 mg | S |
| Practice relaxation breathing most days and lower the GAD-7 score by the six-month review | 1849-09-08 | completed | Daily breathing practice; GAD-7 from 8 to 5 | S |